Compare YSXT & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | VTGN |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 21.8M |
| IPO Year | N/A | 2014 |
| Metric | YSXT | VTGN |
|---|---|---|
| Price | $1.18 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 305.8K | ★ 464.4K |
| Earning Date | 02-03-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $0.43 |
| 52 Week High | $9.90 | $5.14 |
| Indicator | YSXT | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 47.76 |
| Support Level | $1.08 | $0.57 |
| Resistance Level | $1.51 | $0.66 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 20.31 | 48.27 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.